Newly discovered protein blocks sleeping sickness 

New research by the lab of Prof. Jo Van Ginderachter (VIB Center for Inflammation Research and VUB), in collaboration with Prof. Carl De Trez (VUB) and others, identifies a protein that could pave the way toward drugs against sleeping sickness.

Brussels, 28 February 2024 - Human African Trypanosomiasis (HAT), or sleeping sickness, is a neglected tropical disease that affects millions of people and is fatal if left untreated. Most treatments and preventative options, however, are not very effective. New research by the lab of Prof. Jo Van Ginderachter (VIB Center for Inflammation Research and VUB), in collaboration with Prof. Carl De Trez (VUB) and others, identifies a protein that could pave the way toward drugs against sleeping sickness. Their work appears in Nature Communications.  

Sleeping sickness evades the immune system 

Hitchhiking in the gut and mouthparts of the tsetse fly, microscopic parasites known as trypanosomes can cause fatal disease in mammals, including humans. In Sub-Saharan Africa, trypanosomes that infect humans cause sleeping sickness or Human African Trypanosomiasis (HAT). A similar disease in livestock is known as nagana or Animal African Trypanosomiasis (AAT). ​ 

Sleeping sickness is recognized by the World Health Organization as a neglected tropical disease, which affects millions and has high mortality rates. It is also a disease that shows a limited response to medication and for which no vaccine exists. After millions of years of evolution, trypanosomes have gained the ability to effectively escape detection by the immune system and stop potential immune responses in their tracks. How the parasites do this is still largely a mystery. 

Prof. Benoit Stijlemans, first author of the study: “We know that other protozoan parasites use proteins similar to a mammalian protein called Macrophage Migration Inhibitory Factor (MIF) to manipulate the immune system of their victims. So, we went looking for a MIF equivalent in the genomes of trypanosomes that promotes sleeping sickness.” 
Prof. Jo Van Ginderachter and Prof. Benoit Stijlemans
Prof. Jo Van Ginderachter and Prof. Benoit Stijlemans

A protein that stops trypanosomes 

But a protein similar to MIF was not what the researchers found. 

Prof. Jo Van Ginderachter, senior author of the study: “We did not find a MIF homolog in the trypanosome genome, but we did identify another protein that had interesting structural characteristics, called Q586B2.” 

Deleting the gene coding for that protein from the parasite’s genome led to a lower parasite burden in the blood of infected lab mice, as well as prolonged the animals’ survival. This deletion also promoted the differentiation of the parasite into a short stumpy form, which might account for the lower parasite burden. The researchers used their new knowledge to develop two therapeutic strategies for sleeping sickness: a nanobody that blocks the action of Q586B2 designed with the help of the VIB Nanobody Core, and immunization with the protein. For both strategies, this results in a lower parasite burden and longer survival. 

Prof. Jo Van Ginderachter: “The Q586B2 protein is not unique to trypanosomes. It could be the missing piece to develop a broad-spectrum intervention strategy for human diseases such as sleeping sickness, leishmaniasis, and Chagas disease as well as veterinary and economically relevant diseases such as nagana.” 
A graphical summary of the findings.
A graphical summary of the findings.

Publication 

Stijlemans et al. Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatids. Nature Communications, 2024. 

Funding 

This work was supported by the VUB Strategic Research Program, FWO, NIH, FNRS, University of Antwerp, and KU Leuven. ​ 


Questions from patients 

A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address. 

About the VIB-UGent Center for Inflammation Research 

Inflammation is your body’s response to infection or injury. Normally this is a good defense mechanism. But if something goes wrong with the way this mechanism is controlled, it may result in diseases such as asthma, Crohn's disease or rheumatoid arthritis. The VIB-UGent Center for Inflammation Research investigates the mechanisms that underlie these diseases, they can develop new treatments and improve existing therapies. 


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB
Joran Lauwers

Joran Lauwers

Science & Business Communications Expert, VIB

 

Share

Latest News

Website preview
Scientists create protein ‘seeds’ that trigger key pathological features of ALS and frontotemporal dementia
28 March 2024, Leuven, Belgium — Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, researchers report ‘seeding’ this accumulation through fragments of the culprit protein created in the lab. The findings provide further evidence for a prion-like paradigm wherein protein aggregation occurs in a templated fashion. This breakthrough provides the research field with a powerful way to model and study the mechanisms driving neurodegeneration.
press.vib.be
Website preview
Reprogramming immune cells to improve cancer treatment
Scientists at the VIB-KU Leuven Center for Cancer Biology and their collaborators demonstrated a remarkable ability to boost the immune system's fight against cancer
press.vib.be
Website preview
New insights into plant growth - Asymmetric distribution of brassinosteroids after mitotic cell division
Researchers at the VIB-UGent Center for Plant Systems Biology have revealed crucial insights into the role brassinosteroids – essential plant hormones – play in regulating cell division and growth
press.vib.be

About VIB

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be